Soligenix grants CFO 100,000 stock options at $ 1.63 exercise

Soligenix, Inc. reported an insider equity award to its Chief Financial Officer, Jonathan L. Guarino.

Rhea-AI Filing Summary

Soligenix, Inc. reported an insider equity award to its Chief Financial Officer, Jonathan L. Guarino. He received a stock option grant covering 100,000 options to purchase common stock at an exercise price of $ 1.63 per share on December 11, 2025.

The option expires on December 10, 2035. It vested immediately as to 25% of the shares, with the remaining 75% scheduled to vest in 12 equal installments on each three month anniversary of December 11, 2025. Following this grant, he beneficially owns 100,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Guarino Jonathan L.

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Option (Right to Buy)	100,000	$0.00	$0.00

Holdings After Transaction: Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vested immediately as to 25% of the shares and vests as to the remaining 75% of the shares in 12 equal installments (or nearly equal installments if the number of remaining shares is not evenly divisible by 12) on each three (3) month anniversary of December 11, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Soligenix (SNGX) disclose in this filing?

Soligenix disclosed that its Chief Financial Officer, Jonathan L. Guarino, received a new stock option grant for 100,000 options to purchase Soligenix common stock.

How many Soligenix stock options did CFO Jonathan L. Guarino receive?

The CFO received 100,000 stock options as reported in Table II of the filing.

What is the exercise price and expiration date of the new Soligenix options?

The options have an exercise price of $ 1.63 per share and an expiration date of 12/10/2035.

How do the Soligenix CFO stock options vest?

The filing states that the stock option vested immediately as to 25% of the shares and that the remaining 75% of the shares vest in 12 equal installments on each three month anniversary of December 11, 2025.

Is the reporting person a director or officer of Soligenix?

The reporting person is an officer of Soligenix, serving as CFO (Chief Financial Officer), and is not marked as a director or 10% owner.

How many derivative securities does the Soligenix CFO beneficially own after this transaction?

After this option grant, the CFO is reported to beneficially own 100,000 derivative securities directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/12/2025 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guarino Jonathan L.

(Last) (First) (Middle)

C/O SOLIGENIX, INC.

29 EMMONS DRIVE, SUITE B-10

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)(1)	$1.63	12/11/2025		A		100,000		12/11/2025	12/10/2035	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The stock option vested immediately as to 25% of the shares and vests as to the remaining 75% of the shares in 12 equal installments (or nearly equal installments if the number of remaining shares is not evenly divisible by 12) on each three (3) month anniversary of December 11, 2025.

	/s/ Jonathan L. Guarino	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.